Passage Bio (PASG) Projected to Post Quarterly Earnings on Tuesday

Passage Bio (NASDAQ:PASG) will likely be issuing its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($2.19) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

Passage Bio Trading Up 5.3%

Shares of PASG opened at $9.12 on Friday. Passage Bio has a 12-month low of $5.12 and a 12-month high of $20.00. The stock has a market cap of $29.00 million, a P/E ratio of -0.63 and a beta of 1.72. The company has a 50-day moving average of $11.66 and a two-hundred day moving average of $9.26.

Insiders Place Their Bets

In other Passage Bio news, CEO William Chou sold 4,076 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $18.44, for a total value of $75,161.44. Following the completion of the transaction, the chief executive officer directly owned 6,524 shares in the company, valued at approximately $120,302.56. The trade was a 38.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Passage Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in PASG. Quadrature Capital Ltd acquired a new position in Passage Bio in the fourth quarter valued at $148,000. Squarepoint Ops LLC purchased a new stake in Passage Bio in the 3rd quarter valued at about $188,000. Geode Capital Management LLC increased its stake in shares of Passage Bio by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock valued at $371,000 after acquiring an additional 4,114 shares during the last quarter. Yiheng Capital Management L.P. acquired a new position in shares of Passage Bio during the 4th quarter valued at about $405,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Passage Bio by 8.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock worth $1,287,000 after acquiring an additional 8,300 shares during the period. Hedge funds and other institutional investors own 53.48% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on PASG shares. Weiss Ratings restated a “sell (d-)” rating on shares of Passage Bio in a research report on Monday, December 29th. Chardan Capital initiated coverage on Passage Bio in a research report on Tuesday, February 10th. They set a “buy” rating and a $21.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.67.

Passage Bio Company Profile

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.